ABSTRACT
Middle East respiratory syndrome (MERS) is an emerging infectious disease caused by the betacoronavirus (MERS-CoV). Since the isolation and identification of MERS-CoV in 2012, cases have been spread to neighboring nations in Arabian Peninsula area and Europe. The recent outbreak of MERS in Korea confirmed that MERS-CoV is capable of causing epidemics through person-to-person transmission. Despite of its high mortality, there is no available effective vaccine and therapeutic agent partly due to its short history. So far, ribavirin and interferon therapy has been failed to prove its efficacy in human patients. Thus, there is an urgent need for the effective countermeasures such as vaccines and therapeutics. In the current review, recent advances in the development of vaccines and therapeutic antibodies have been discussed.
Subject(s)
Humans , Antibodies , Communicable Diseases, Emerging , Europe , Interferons , Korea , Middle East , Mortality , Ribavirin , VaccinesABSTRACT
Human Respiratory Syncytial virus (hRSV) is a leading cause of severe lower respiratory tract diseases in the pediatric population.hRSV frequently causes severe morbidity and mortality in high risk groups including infants with congenital heart disease and the immunosuppressed patients. Although hRSV is recognized as a major public health threat and economic burden worldwide, there is no licensed vaccine and effective therapeutic agent. Viral nonstructural (NS) proteins have been known to play multiple functions for efficient viral replication and pathogenesis. Especially, diverse functions of influenza A virus NS1 have been extensively studies. Recent studies demonstrated that NS1 and NS2 of RSV also exert diverse functions to modulate cellular environment and antiviral immune responses. Since NS proteins of RSV are required for efficient replication and pathogenesis, NS mutant viruses have been tested as live-attenuated vaccines. This review will outline the recent progress in understanding the various functions of RSV NS1 and NS2.